Based on this evidence, our hypothesis is that IL-1, via IL-1R1, promotes the induction of intestinal ILC3 cells and reinforces the intestinal barrier through of the production of IL-22, as well as the improvement of metabolic and inflammatory changes associated with obesity and MS. Here, IL1B is linked to myeloid sarcoma.